Suppr超能文献

疑似遗传性自身炎症性疾病中基因panel 阳性的预测临床和生物学标准:一项病例对照研究的启示。

Predictive Clinical and Biological Criteria for Gene Panel Positivity in Suspected Inherited Autoinflammatory Diseases: Insights from a Case-Control Study.

机构信息

Laboratoire de Génétique des Maladies Rares et Autoinflammatoires, Service de Génétique Moléculaire et Cytogénomique, National Reference Center for Autoinflammatory Diseases and AA Amyloidosis, Centre Hospitalier Universitaire Montpellier, Université de Montpellier, 34295 Montpellier, France.

Stem Cells, Cellular Plasticity, Regenerative Medicine and Immunotherapies, INSERM, 34295 Montpellier, France.

出版信息

Genes (Basel). 2023 Oct 14;14(10):1939. doi: 10.3390/genes14101939.

Abstract

In order to assess the clinical and biological criteria that predict gene panel positivity in patients with a suspected inherited genetic autoinflammatory disease, we conducted a case-control study. These new selection criteria could replace the national multidisciplinary staff approval before performing genetic testing that has been required since 2019. The study involved 119 positive gene panels matched by panel sizes to 119 randomly selected negative gene panels. The patients were referred to our laboratory for genetic testing between June 2012, and March 2023. The clinical and biological criteria were extracted from a prospectively filled database. We focused our evaluation on accuracy and the positive predictive value. Neonatal symptom onset and deafness had the highest accuracies among all criteria associated with the positivity panel, with 92.9% (88.6; 96.0) and 92.6% (88.5; 95.6), respectively. However, it is important to note that the associated Positive Predictive Values (PPVs) cannot exceed 50%. Despite finding a statistical association between clinical and biological criteria and panel positivity, the predictive values of these criteria were not sufficient to recommend Next-Generation Sequencing (NGS) gene panel testing without the national multidisciplinary staff evaluation.

摘要

为了评估预测疑似遗传性自身炎症性疾病患者基因panel 阳性的临床和生物学标准,我们进行了一项病例对照研究。这些新的选择标准可以替代自 2019 年以来进行基因检测前所需的全国多学科工作人员批准。该研究纳入了 119 个阳性基因panel,这些 panel 的大小与 119 个随机选择的阴性基因panel 相匹配。这些患者在 2012 年 6 月至 2023 年 3 月期间被转介到我们实验室进行基因检测。临床和生物学标准是从一个前瞻性填写的数据库中提取的。我们专注于评估准确性和阳性预测值。与阳性panel 相关的所有标准中,新生儿症状发作和耳聋的准确率最高,分别为 92.9%(88.6;96.0)和 92.6%(88.5;95.6)。然而,需要注意的是,相关的阳性预测值(PPV)不能超过 50%。尽管发现临床和生物学标准与 panel 阳性之间存在统计学关联,但这些标准的预测值不足以在没有全国多学科工作人员评估的情况下推荐下一代测序(NGS)基因panel 检测。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dbdd/10606291/9345e40eeb17/genes-14-01939-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验